Buy Urispas
Urispas

$1.19
Active Ingredient
Delivery
Airmail (14-21 days) | EMS trackable (5-9 days)
Prescription
Issued on site / Included
Availability
In Stock
Product is shipped in a fully discreet envelope with no content disclosure, including all required documentation inside

Urispas Properties

Active Ingredients
Primary Category
Pharmacological Class
Muscarinic Antagonists
Minor Side Effects
Moderate Side Effects
Dosage Forms
Tablets
Administration Route
Oral
Mechanism of Action
Helps relax the muscles in the bladder and urinary tract, which can reduce spasms and alleviate symptoms like frequent or painful urination and urgency.
Prescription Status
Rx
Patient Summary
Used to relieve symptoms associated with overactive bladder and other urinary tract irritations.
Onset Time
Within an hour or two
Duration
Several hours
Storage Instructions
Store at room temperature, away from moisture
Age Restrictions
Not typically for use in children under 12
Pregnancy Use
Consult doctor before use during pregnancy or breastfeeding
Alternative Drugs

About Urispas

Generic Urispas (Flavoxate) is a prescription-only antispasmodic formulated as a 200 mg oral tablet and marketed for the management of uncomfortable urinary symptoms such as urgency, frequency, and painful bladder spasm. It belongs to the class of smooth-muscle relaxants and works by dampening involuntary contractions of the urinary tract, helping patients regain control over their bladder function. While the active ingredient, flavoxate, is recognized in several countries for urinary tract care, its availability in Singapore is limited, making it a candidate for those seeking a specialized therapeutic option through qualified channels.

What is Generic Urispas (Flavoxate)?

Generic Urispas (Flavoxate) contains the active moiety flavoxate hydrochloride, a synthetic anticholinergic-like agent that exerts a direct relaxant effect on smooth muscle. The product is regulated as a prescription medication in jurisdictions where it is approved, and it is classified under the therapeutic category of urinary tract care. In Singapore, flavoxate is not listed on the Health Sciences Authority’s (HSA) Register of Medicines, which means it is not commercially stocked by local pharmacies; however, qualified physicians may still prescribe it under special access schemes when clinical judgment deems it appropriate. The tablet form (200 mg) is designed for oral administration, usually taken two to three times daily depending on the severity of symptoms and the prescribing clinician’s assessment.

How Urispas Works

Flavoxate’s mechanism centers on the modulation of intracellular calcium dynamics within smooth-muscle cells. By inhibiting calcium influx through voltage-gated channels, the drug reduces the contractile force of the detrusor muscle-the muscle that contracts to expel urine. This attenuation of muscle tone lessens involuntary spasms that are responsible for urgency and painful bladder sensations.

Pharmacokinetically, flavoxate is well-absorbed from the gastrointestinal tract, reaching peak plasma concentrations within 1-2 hours after ingestion. It undergoes hepatic metabolism principally via the cytochrome P450 system (CYP3A4), yielding inactive metabolites that are excreted renally. The elimination half-life ranges from 7 to 10 hours, supporting a dosing interval of 8-12 hours to maintain therapeutic plasma levels. Food does not markedly affect absorption, allowing flexibility in timing relative to meals.

Because flavoxate acts directly on smooth muscle rather than through muscarinic receptor blockade, it produces fewer classic anticholinergic side effects such as dry mouth or blurred vision. Nonetheless, systemic exposure can still lead to mild adverse reactions that are discussed below.

Why Urispas Is Used for Urinary Tract Care

  • Overactive bladder (OAB) and urgency-frequency syndrome - Flavoxate’s ability to relax the detrusor muscle directly addresses the pathophysiology of OAB, where hyperactive smooth-muscle contractions trigger sudden urges. Clinical guidelines from the International Continence Society list antispasmodics as adjuncts when first-line antimuscarinics are insufficient or poorly tolerated.
  • Interstitial cystitis/bladder pain syndrome - Although not a primary indication, several small open-label studies have reported symptom relief with flavoxate, likely due to its spasm-relieving properties. It may be considered in refractory cases under specialist supervision.
  • Post-operative bladder spasm - After urological procedures, temporary irritation of the bladder wall can provoke painful spasms. Short-term flavoxate can smooth the recovery trajectory by dampening these contractions.

In each scenario, the drug’s direct smooth-muscle effect complements other modalities (behavioral therapy, pelvic-floor training) and offers a mechanistically distinct option for patients who cannot achieve adequate control with antimuscarinic agents alone.

Off-Label and Investigational Uses of Urispas

Current peer-reviewed literature does not provide robust evidence for widespread off-label applications of flavoxate beyond the urinary tract. Isolated case reports have explored its use in esophageal spasm and biliary colic, but these indications lack randomized controlled trials and are not recognized by regulatory authorities in Singapore.

Off-label use should only be considered under the supervision of a qualified healthcare provider.

Is Urispas Right for You?

Urispas may be appropriate for adults who experience persistent urinary urgency, frequency, or bladder pain that has not responded adequately to first-line therapies. Ideal candidates often present with documented detrusor overactivity on urodynamic testing or have exhausted antimuscarinic options due to intolerable side effects.

Special populations require careful assessment:

  • Elderly patients - Age-related renal decline can prolong flavoxate elimination; dose adjustments or extended dosing intervals may be necessary.
  • Pregnancy and lactation - Safety data are insufficient; the drug is generally avoided unless the potential benefit outweighs fetal risk.
  • Renal or hepatic impairment - Reduced clearance may increase plasma concentrations; clinicians should monitor for heightened adverse effects and consider lower initial doses.

Contraindications such as known hypersensitivity to flavoxate, severe gastrointestinal obstruction, or acute urinary retention should be respected, as highlighted in the product’s prescribing information.

Taking Urispas Effectively

  • Timing - Take the tablet with a full glass of water, preferably at evenly spaced intervals (e.g., every 8 hours) to maintain steady plasma levels.
  • Food interactions - Because absorption is not food-dependent, you may ingest Urispas with or without meals according to personal convenience.
  • Missed dose - If you miss a dose and it is less than 4 hours until the next scheduled dose, take the missed tablet immediately. Skip it if the interval would be shorter than 4 hours, and resume the regular schedule.
  • Travel considerations - When crossing borders, retain the original prescription label and a copy of the clinician’s note to satisfy customs authorities. Store tablets at room temperature, away from moisture and direct sunlight.

Adhering to these practical tips can maximise therapeutic benefit while minimizing the risk of suboptimal plasma concentrations or accidental overdose.

Understanding Side Effects and How to Manage Them

Flavoxate’s side-effect profile reflects its smooth-muscle-relaxant action and systemic exposure:

  • Common (1-10 %): mild dizziness, headache, and transient gastrointestinal discomfort (nausea, abdominal cramping). These effects often resolve within the first week the adapts. Managing dizziness includes standing up slowly and avoiding activities that require immediate balance (e.g., driving) until tolerance is established.
  • Less common (.1-1 %): hypotension or fainting, particularly in patients on concurrent antihypertensive agents. Monitoring blood pressure after initiation can preempt serious events.
  • Rare but serious: severe allergic reactions (rash, angioedema, bronchospasm) or signs of urinary retention. Prompt medical evaluation is warranted if any of these occur.

When side effects interfere with daily life, dose reduction or temporary discontinuation under physician guidance may be advisable. Never self-adjust the regimen without professional input.

Buying Urispas from Our Online Pharmacy

Access to Urispas can be challenging in Singapore due to its limited market presence. Our online pharmacy offers a discreet, reliable pathway to obtain the medication when a qualified prescriber has provided a valid prescription.

Why Choose Our Service?

  • Convenient access - Order from the comfort of your home and avoid long pharmacy queues.
  • Competitive pricing - We source Urispas through licensed international partners, often achieving savings of up to 30 % compared with overseas retail rates.
  • Secure handling - All shipments are processed through our vetted network, ensuring product integrity and compliance with Singaporean import regulations.

Quality & Safety

Our platform works exclusively with pharmacies that adhere to WHO-GMP standards and hold valid export licences. Each batch of Urispas is packaged in tamper-evident containers and accompanied by a full product information leaflet in English.

Pricing & Access

The typical cost for a 30-tablet supply of 200 mg Urispas is SGD 78, with a Lifetime 10 % discount on all reorders for registered users. We also provide a price-match guarantee for verified lower offers from other licensed sources.

Discreet Delivery

Orders are shipped via express courier (delivery in ~7 days) or standard mail (delivery within 3 weeks). Packages are unbranded and placed in neutral-colored envelopes to protect your privacy.

Frequently Asked Questions

  • What distinguishes flavoxate from antimuscarinic drugs? Flavoxate relaxes bladder smooth muscle by blocking calcium influx rather than antagonising muscarinic receptors. This results in fewer typical anticholinergic side effects such as dry mouth or blurred vision.

  • Can I take Urispas if I am already on a blood pressure medication? Because flavoxate can occasionally lower blood pressure, it is advisable to have your clinician review your antihypertensive regimen. Monitoring blood pressure after starting Urispas helps detect any additive effect early.

  • Is Urispas effective for nighttime urinary urgency? By reducing involuntary detrusor contractions, flavoxate can lessen nocturnal urgency for many patients. Clinical observations suggest improvement in sleep quality when the drug is taken in the evening as part of a divided-dose schedule.

  • How quickly will I notice symptom relief? Most patients report a perceptible decrease in urgency within 3-5 days of consistent dosing, though full benefit may take up to two weeks as the medication reaches steady-state concentrations.

  • Are there any dietary restrictions while taking Urispas? There are no specific food bans. However, excessive caffeine or alcohol can exacerbate bladder irritation and might blunt the drug’s effect, so moderation is recommended.

  • Can I use Urispas for prostate enlargement symptoms? Flavoxate is not indicated for benign prostatic hyperplasia (BPH). While it may alleviate bladder spasm associated with BPH, a prostate-targeted therapy (e.g., alpha-blocker) is typically required for optimal management.

  • What should I do if I miss a dose while traveling abroad? Follow the missed-dose guidance in the “Taking Urispas Effectively” section. Keep the prescription label handy for customs officials, and ensure you have a copy of the prescribing doctor’s note in case verification is needed.

  • Is Urispas covered by Singapore’s MediSave or private insurance? As a non-listed medication, Urispas is generally not reimbursed by MediSave or typical private health plans. Patients often bear the out-of-pocket cost unless they have a supplemental policy that includes special-access drugs.

  • Can Urispas be used in combination with pelvic-floor physiotherapy? Yes. Combining pharmacologic smooth-muscle relaxation with targeted pelvic-floor exercises can provide synergistic improvement in urinary control, especially for refractory overactive bladder.

  • What monitoring is required after starting Urispas? Baseline renal and hepatic function tests are prudent, followed by periodic assessment (every 3-6 months) to ensure safe metabolism and elimination, particularly in older adults or those with known organ impairment.

  • Is there a risk of dependence or tolerance with long-term use? Flavoxate does not exhibit addictive properties, and tolerance is uncommon. Nonetheless, clinicians typically reassess the need for continued therapy annually to confirm ongoing benefit.

Glossary

Detrusor muscle
The smooth-muscle wall of the bladder that contracts to expel urine.
Calcium influx
The movement of calcium ions into a cell, which triggers muscle contraction; flavoxate blocks this pathway in bladder smooth muscle.
Pharmacokinetics
The study of how a drug is absorbed, distributed, metabolized, and excreted by the body.
Urodynamic testing
Diagnostic procedures that evaluate the function of the bladder and urethra, often used to confirm detrusor overactivity.
GMP (Good Manufacturing Practice)
International quality standards that ensure medicines are consistently produced and controlled according to quality criteria.

Disclaimer

The information provided about Urispas is for general knowledge only and does not replace professional medical consultation. All treatment decisions, including those regarding off-label use, should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Urispas for individuals who may have limited availability through traditional pharmacies, prescription-based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.

External Resources about Urispas


Information Prepared By

Nawin Kittisak
Vikneswaran V Paranjothy